CLOs on the Move

Open Door Health

www.opendoorhs.org

 
Open Door Health Services has local healthcare clinics in Muncie & Anderson IN. Visit our site to learn about affordable health services. Contact us today!
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Shionogi USA Inc

Shionogi USA Inc is a Florham Park, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Prometheus Laboratories

Prometheus Laboratories Inc. is one of the leading companies in the Healthcare, Pharmaceuticals and Biotech sector.

Jamieson Wellness

Jamieson Wellness is a Canadian company that manufactures, distributes, and markets high quality natural health products. Their portfolio includes the Jamieson brand, which is Canadas #1 consumer health brand, as well as the youtheory, Progressive, Sm...

Trio Health

Trio Health offers a unique collaboration with clinical experts, patients and specialty pharmacies to allow unparalleled insight into patient care. Together with our advisory boards, we created Trio Health MDX, a proprietary system to collect and share information from all three stakeholders. This innovative collaboration provides the patient with unprecedented care thereby improving patient outcomes.

ORIC Pharmaceuticals

ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors. ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.